Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pyrinuron** is a synthetic organic compound, formerly used as a rodenticide under the trade names Vacor and Pyriminil. It acts primarily as a vitamin B6 (pyridoxine) antagonist, disrupting the utilization of vitamin B6 and leading to deficiency[10][12]. It selectively destroys insulin-producing pancreatic beta cells, often causing type 1 diabetes in humans and animals through a mechanism involving the formation of Vacor-mononucleotide (VMN) and subsequent activation of SARM1, leading to NAD+ depletion and cell death[10][12]. Pyrinuron is also an inhibitor of the enzymes nicotinamide phosphoribosyltransferase (NAMPT) and NMN adenylyltransferase 2 (NMNAT2)[4][12]. Due to high toxicity, risks of secondary poisoning, and the induction of diabetes, its commercial use as a pesticide has been discontinued since 1979, and it is not registered or approved by regulatory agencies for any therapeutic or agricultural use[1][13]. Pyrinuron remains a subject of research, particularly for experimental induction of diabetes and vitamin B6 deficiency in laboratory settings[10][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyrinuron.